



Biomarkers in Chronic Kidney Disease

Guest Editors:

Prof. Dr. Francisco Herrera-Gómez

1. Kidney Resuscitation and
Acute Purification Therapies,
Sanidad de Castilla y León and
University of Valladolid, Zamora
and Valladolid, Spain
2. Transplantation Center,
Lausanne University Hospital and
University of Lausanne,
Lausanne, Switzerland

Prof. Dr. F. Javier Álvarez

Pharmacological Big Data
Laboratory, Faculty of Medicine,
University of Valladolid, 47005
Valladolid, Spain

Deadline for manuscript
submissions:

closed (30 April 2021)

Message from the Guest Editors

Dear Colleagues,

In the evaluation of the real impact of medicines along the wide spectrum of chronic kidney disease (CKD), authentic treatment-effect modifiers, i.e., markers of the effect of medicines, and independent prognostic factors, i.e., markers of the likely progress of a disease regardless of the treatment given, are urgently needed in order to personalize therapies in this population. Also known as a predictive biomarker, the status of treatment effect modifiers changes in accordance with the effect of a given medicine, so it may be used to discern between good and poor responders. This Special Issue on Biomarkers in Chronic Kidney Disease is thus aimed as a compilation of original research articles and review articles on potential candidates to predictive and prognostic biomarkers in this susceptible population.

Prof. Dr. Francisco Herrera-Gómez

Prof. Dr. F. Javier Álvarez

Guest Editors





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and
Center for Clinical Research

Learning, Spaulding
Rehabilitation Hospital and
Massachusetts General Hospital,
Harvard Medical School, Boston,
MA 02114, USA

2. Department of Epidemiology,
Harvard T.H. Chan School of
Public Health, Boston, MA 02115,
USA

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Author Benefits

Open Access: free for readers, with [article processing charges \(APC\)](#) paid by authors or their institutions.

High Visibility: indexed within [Scopus](#), [SCIE \(Web of Science\)](#), [PubMed](#), [PMC](#), [CAPUS / SciFinder](#), and [other databases](#).

Journal Rank: JCR - Q1 (*Pharmacology & Pharmacy*) / CiteScore - Q2 (*Medicine (miscellaneous)*)

Contact Us

Biomedicines Editorial Office
MDPI, St. Alban-Anlage 66
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/biomedicines
biomedicines@mdpi.com
[X@Biomed_MDPI](#)